Long-term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets in the CLARITY and CLARITY Extension Studies

被引：0
|
作者：
Giovannoni, G. [1 ]
Comi, G. [2 ,3 ]
Rammohan, K. [4 ]
Rieckmann, P. [5 ,6 ]
Vermersch, P. [7 ]
Dangond, F. [8 ]
Keller, B. [9 ]
Jack, D. [9 ]
机构：
[1] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England
[2] Univ Vita Salute San Raffaele, Dept Neurol, Osped San Raffaele, Milan, Italy
[3] Univ Vita Salute San Raffaele, Inst Expt Neurol, Osped San Raffaele, Milan, Italy
[4] Univ Miami, Sch Med, MS Res Ctr, Miami, FL USA
[5] Med Pk Loipl, Ctr Clin Neuroplast, Erlangen, Germany
[6] Univ Erlangen Nurnberg, Erlangen, Germany
[7] Univ Lille, INSERM, CHU Lille, FHU Imminent,U1172, Lille, France
[8] EMD Serono Res & Dev Inst Inc, Billerica, MA USA
[9] Merck KGaA, Darmstadt, Germany
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2020年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPR3084
引用
收藏
页码：468 / 468
页数：1
相关论文
共 50 条
  • [41] Benefits of cladribine tablets on the achievement of no evidence of disease activity (NEDA) status in patients with multiple sclerosis: analysis of pooled double-blind data from the CLARITY and ONWARD studies
    Giovannoni, G.
    Montalban, X.
    Hicking, C.
    Dangond, F.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 303 - 304
  • [42] Analysis of clinical and radiological disease activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets, in the double-blind, 96-week CLARITY study
    Giovannoni, G.
    Comi, G.
    Cook, S.
    Rammohan, K.
    Rieckmann, P.
    Sorensen, P. Soelberg
    Vermersch, P.
    Chang, P.
    Hamlett, A.
    Verjee, R.
    Musch, B.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2010, 257 : S21 - S21
  • [43] Analysis of clinical and radiological disease activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets, in the double-blind, 96-week CLARITY study
    Giovannoni, G.
    Comi, G.
    Cook, S.
    Rammohan, K.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Chang, P.
    Hamlett, A.
    Fevr, T.
    Musch, B.
    Greenberg, S. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 215 - 215
  • [44] Analysis of Clinical and Radiological Disease Activity-Free Status in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets, in the Double-Blind, 96-Week CLARITY Study
    Giovannoni, Gavin
    Cami, Giancarlo
    Cook, Stuart
    Rammohan, Kottil
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Chang, Peter
    Hamlett, Anthony
    Veriee, Rehan
    Musch, Bruno
    Greenberg, Steven
    NEUROLOGY, 2010, 74 (09) : A295 - A296
  • [45] Disease activity as assessed by the MAGNIMS Score predicts long-term clinical disease activity free status and disability progression in patients treated with subcutaneous interferon beta-1a
    Sormani, M. P.
    Freedman, M. S.
    Aldridge, J.
    Marhardt, K.
    De Stefano, N.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 387 - 387
  • [46] Magnetic resonance imaging (MRI) outcomes in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets: results from the 120-week Phase IIIb extension of the CLARITY study
    Comi, G.
    Giovannoni, G.
    Cook, S.
    Rieckmann, P.
    Rammohan, K.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Martin, E.
    Dangond, F.
    SWISS MEDICAL WEEKLY, 2016, 146 : 77S - 77S
  • [47] Magnetic Resonance Imaging (MRI) Outcomes in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets: Results from the 120-Week Phase IIIb Extension of the CLARITY Study
    Giancarlo, Comi
    Ciovannoni, Gavin
    Cook, Stuart
    Rammohan, Kottil
    Soelberg-Soerensenn, Per
    Vermersch, Patrick
    Martin, Emily
    Dangond, Fernando
    Rieckmann, Peter
    NEUROLOGY, 2016, 86
  • [48] Disease activity as assessed by the MAGNIMS score predicts long-term clinical disease activity (CDA)-free status and disability progression in patients treated with subcutaneous interferon beta-1a
    Sormani, M. P.
    Freedman, M. S.
    Aldridge, J.
    Marhardt, K.
    de Stefano, N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 318 - 318
  • [49] Slowing of Disability Progression Based on 6-Month Confirmed EDSS in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets in the CLARITY Study: A Post-Hoc Subgroup Analysis
    Cook, Stuart
    Rammohan, Kottil
    Rieckmann, Peter
    Soelberg-Sorensenn, Per
    Vermersch, Patrick
    Hicking, Christine
    Dangond, Fernando
    Ciovannoni, Gavin
    NEUROLOGY, 2016, 86
  • [50] Walking speed, rather than Expanded Disability Status Scale, relates to long-term patient-reported impact in progressive MS
    Bosma, L. V. A. E.
    Kragt, J. J.
    Polman, C. H.
    Uitdehaag, B. M. J.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (03) : 326 - 333
12345